-
Je něco špatně v tomto záznamu ?
5-azacytosine compounds in medicinal chemistry: current stage and future perspectives
M. Krečmerová, M. Otmar
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem, přehledy
PubMed
22650240
DOI
10.4155/fmc.12.36
Knihovny.cz E-zdroje
- MeSH
- antitumorózní látky chemie farmakologie terapeutické užití MeSH
- azacytidin analogy a deriváty chemie farmakologie terapeutické užití MeSH
- cytosin analogy a deriváty chemie farmakologie terapeutické užití MeSH
- HIV infekce farmakoterapie MeSH
- HIV účinky léků MeSH
- látky proti HIV chemie farmakologie terapeutické užití MeSH
- lidé MeSH
- metylace DNA účinky léků MeSH
- nádory farmakoterapie MeSH
- objevování léků MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
This review summarizes the basic milestones of the research of 5-azacytosine nucleosides chronologically from their discovery and anticancer activity identification, through to subsequent unveiling of their mechanism of action based on DNA hypomethylation and tumor-suppressor gene reactivation, to the final US FDA approval of 5-azacytidine (Vidaza(®)) and 2'-deoxy-5-azacytidine (Dacogen(®)) for the treatment of myelodysplastic syndromes. 5,6-dihydro-2'-deoxy-5-azacytidine, a compound with anti-HIV activity through lethal mutagenesis, representing a unique mechanism of action among existing anti-retroviral drugs, is discussed together with quite recent discovery of its so far unexpected hypomethylation activity. Special attention is paid to 5-azacytosine acyclic nucleoside analogues and phosphonomethyl derivatives with the emphasis on the new potent anti-DNA virus agent (S)-1-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine and its prodrug forms. Considering the potential pharmaceutical applications, 5-azacytosine and 5,6-dihydro-5-azacytosine appear to be so far the most effective cytosine mimics for the design of novel antiviral and anti-tumor drug candidates.
- 000
- 00000naa a2200000 a 4500
- 001
- bmc12034469
- 003
- CZ-PrNML
- 005
- 20160626101533.0
- 007
- ta
- 008
- 121023s2012 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.4155/fmc.12.36 $2 doi
- 035 __
- $a (PubMed)22650240
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Krečmerová, Marcela $7 _AN040502 $u Institute of Organic Chemistry & Biochemistry, Academy of Sciences of the Czech Republic, v.v.i., Flemingovo nam. 2, 16610 Prague 6, Czech Republic. marcela@uochb.cas.cz
- 245 10
- $a 5-azacytosine compounds in medicinal chemistry: current stage and future perspectives / $c M. Krečmerová, M. Otmar
- 520 9_
- $a This review summarizes the basic milestones of the research of 5-azacytosine nucleosides chronologically from their discovery and anticancer activity identification, through to subsequent unveiling of their mechanism of action based on DNA hypomethylation and tumor-suppressor gene reactivation, to the final US FDA approval of 5-azacytidine (Vidaza(®)) and 2'-deoxy-5-azacytidine (Dacogen(®)) for the treatment of myelodysplastic syndromes. 5,6-dihydro-2'-deoxy-5-azacytidine, a compound with anti-HIV activity through lethal mutagenesis, representing a unique mechanism of action among existing anti-retroviral drugs, is discussed together with quite recent discovery of its so far unexpected hypomethylation activity. Special attention is paid to 5-azacytosine acyclic nucleoside analogues and phosphonomethyl derivatives with the emphasis on the new potent anti-DNA virus agent (S)-1-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine and its prodrug forms. Considering the potential pharmaceutical applications, 5-azacytosine and 5,6-dihydro-5-azacytosine appear to be so far the most effective cytosine mimics for the design of novel antiviral and anti-tumor drug candidates.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a látky proti HIV $x chemie $x farmakologie $x terapeutické užití $7 D019380
- 650 _2
- $a antitumorózní látky $x chemie $x farmakologie $x terapeutické užití $7 D000970
- 650 _2
- $a azacytidin $x analogy a deriváty $x chemie $x farmakologie $x terapeutické užití $7 D001374
- 650 _2
- $a cytosin $x analogy a deriváty $x chemie $x farmakologie $x terapeutické užití $7 D003596
- 650 _2
- $a metylace DNA $x účinky léků $7 D019175
- 650 _2
- $a objevování léků $7 D055808
- 650 _2
- $a HIV $x účinky léků $7 D006678
- 650 _2
- $a HIV infekce $x farmakoterapie $7 D015658
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a nádory $x farmakoterapie $7 D009369
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Otmar, Miroslav $7 xx0121125 $u Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Flemingovo nám. 2, 166 10 Prague 6, Czech Republic. otmar@uochb.cas.cz
- 773 0_
- $w MED00180228 $t Future medicinal chemistry $x 1756-8927 $g Roč. 4, č. 8 (2012), s. 991-1005
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/22650240 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20121023 $b ABA008
- 991 __
- $a 20160626101717 $b ABA008
- 999 __
- $a ok $b bmc $g 956479 $s 791966
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2012 $b 4 $c 8 $d 991-1005 $i 1756-8927 $m Future medicinal chemistry $n Future Med Chem $x MED00180228
- LZP __
- $b NLK122 $a Pubmed-20121023